Skip to main content
. 2014 Apr 25;3(2):e000693. doi: 10.1161/JAHA.113.000693

Figure 9.

Figure 9.

Dual modulation of mPTP and redox signaling synergistically promotes cardiomyogenesis. A, Representative FACS analysis of H2DCFDA fluorescence intensity and the percentage of relative mean fluorescence intensity of H2DCFDA incubated with control vehicle (Con), CsA (2 μg/mL), NIM811 (3.6 μg/mL), and FK506 (100 ng/mL). B, Dose‐response curves of Trolox (100 to 1600 μmol/L) and NAC (100 to 1600 μg/mL) with or without CsA (2 μg/mL) for the percentage of cTnT+ cardiomyocytes. C, Representative FACS analysis of cTnT+ cardiomyocytes incubated with control vehicle, CsA (2 μg/mL), Trolox (1600 μmol/L), NAC (1600 μg/mL), tBHP (32 μmol/L), CsA+Trolox (1600 μmol/L), CsA+NAC (1600 μg/mL) and CsA+tBHP (32 μmol/L). D, Dose‐response curves of tBHP (2 to 32 μmol/L) with or without CsA (2 μg/mL) for the percentage of cTnT+ cardiomyocytes. E, Representative FACS analysis of H2DCFDA, 2′,7′‐dichlorodihydrofluorescein diacetate fluorescence intensity and the percentage of relative mean fluorescence intensity of H2DCFDA incubated with control vehicle (Con), CsA (2 μg/mL), Trolox (1600 μmol/L), NAC (1600 μg/mL), CsA+Trolox (1600 μmol/L) and CsA+NAC (1600 μg/mL). F, Representative FACS analysis of H2DCFDA fluorescence intensity and the percentage of relative mean fluorescence intensity of H2DCFDA incubated with control vehicle (Con), CsA (2 μg/mL), tBHP (32 μmol/L) and CsA+tBHP (32 μmol/L). *P<0.01, #P<0.05 and NS (not significant) vs Con or each group. CsA indicates cyclosporin A; cTnT, cardiac Troponin T; H2DCFDA, 2′,7′‐dichlorodihydrofluorescein diacetate; mPTP, mitochondrial permeability transition pore; NAC, N‐acetyl‐L‐cysteine; tBHP, tert‐butyl hydroperoxide.